Share

Today, we would like to share a talk given by Stephen Hilbert, President of Oisin Biotechnologies, in which he discusses treating aging and cancer by removing harmful senescent cells.

On July 12th, we hosted our first conference, Ending Age-Related Diseases: Investment Prospects & Advances in Research, at the Frederick P. Rose Auditorium, which is part of the Cooper Union campus in New York City. The packed event saw a range of people from research, investment, and the wider community coming together for a day of science and biotech business presentations and panels.

One of the companies at the event was Oisin Biotechnologies, a company working on therapies that remove harmful senescent cells, which accumulate as we age and drive aging processes through the senescence-associated secretory phenotype (SASP), which leads to chronic inflammation.

Oisin uses a patented technology combining lipid nanoparticle proteins and suicide-gene-containing DNA plasmids to selectively target and trigger apoptosis in senescent cells.

 

The company is also working on OncoSenX, which is a cancer treatment that uses the same technology but targets a different gene. Oisin anticipates human trials for cancer therapy by 2019, following some very promising mouse results.

We filmed the entire conference and have many more videos of the event coming in the next few months for you to enjoy which you will be added to the NYC video page here. We will also be hosting a second conference in NYC in 2019, as we have decided to make this an annual event.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences. In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project. In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.
Write a comment:

*

Your email address will not be published.

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD